MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate MHC class I expression on papillary thyroid cancer (PTC) and analyze changes in MHC expression and associated immune activation with current and experimental treatments for thyroid cancer using in vitro PTC cell lines. Experimental Design: MHC class I expression and assessment of tumor-infiltrating leukocyte populations were evaluated by immunohistochemistry. PTC cell lines were analyzed for HLA-ABC expression by flow cytometry following tyrosine kinase inhibitor, IFNα or IFNγ, or radiation treatment. Functional changes in antigenicity were assessed by coculture of allogeneic donor peripheral blood leukocytes (PBL) with pretreated or untreated PTC cell lines and measurement of T-cell activation and cytokine production. Results: Both MHC class I and β2-microglobulin expression was reduced or absent in 76% of PTC specimens and was associated with reduced tumor-infiltrating immune cells, including effector (CD3+, CD8+, CD16+) and suppressor (FoxP3+) populations. Treatment of PTC cell lines with the MEK1/2 inhibitor selumetinib or IFN increased HLA-ABC expression. This phenotypic change was associated with increased T-cell activation (%CD25+ of CD3+) and IL2 production by PBL cocultured with treated PTC cell lines. Additive effects were seen with combination selumetinib and IFN treatment. Conclusions: MHC class I expression loss is frequent in human PTC specimens and represents a significant mechanism of immune escape. Increased antigenicity following selumetinib and IFN treatment warrants further study for immunotherapy of progressive PTC. Clin Cancer Res; 20(23); 6034–44. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 2×
“host immune cells (31), highly antigenic tumor cellsmaybe eliminated, selecting for survival of PTCwith lowMHCclass I expression.”
BackgroundReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563 · cited 1×
“Cell lines and cell culture PTC cell lines BCPAP (BRAF mutation), K-1 (BRAF mutation, PI3K mutation), and TPC-1 (RET/ PTC1 translocation, BRAF) were obtained from the University of Colorado Tissue Bank in 2013 and authentication was performed by the University of Colorado Cancer Center DNA Sequencing and Analysis Core…”
MethodGajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145 · cited 1×
“ly 70%of head and neck squamous cell carcinomas, 96%of breast carcinomas, 87% of colon carcinomas, 39% of pancreatic carcinomas, and 63% of melanomas (12, 13).”
Background
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“, breast cancer) contain fewer TIL than their MHC I-high counterparts (10, 11, 120, 121).”
BackgroundInterferon-gamma (IFN-γ): Exploring its implications in infectious diseases
Kak, G., Raza, M., & Tiwari, B. K. (2018) · Biomolecular Concepts · doi:10.1515/bmc-2018-0007 · Cited by 617
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
Metadata
- Authors
- Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L.
- Venue
- Clinical Cancer Research
- Published
- 2014-11-30
- Volume
- 20
- Issue
- 23
- Pages
- 6034-6044
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2136498843
- Cited by
- 152
- References
- 6
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0879
- The paper
- Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L. (2014). MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.